Abstract
Thirty-nine patients with stage III (MO) non-oat cell bronchogenic carcinoma (NOBC) were treated with combined modality therapy: radiation therapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, and procarbazine. The median survival for all patients treated was 9.6 months compared to 6.4 months for historical controls (P = 0.015). Patients who responded to the treatment program had a significantly longer survival (median, 15.2 months) compared to nonresponders and historical controls (P < 0.005). It is concluded that combined modality therapy is moderately effective therapy in stage III (MO) NOBC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 327-332 |
| Number of pages | 6 |
| Journal | Cancer Treatment Reports |
| Volume | 62 |
| Issue number | 3 |
| State | Published - 1978 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research